Literature DB >> 19644472

Tolvaptan.

Jalal K Ghali1, Bashar Hamad, Uma Yasothan, Peter Kirkpatrick.   

Abstract

In May 2009, tolvaptan (Samsca; Otsuka), a selective vasopressin V(2) receptor antagonist, was approved by the US FDA for the treatment of clinically significant hypervolaemic and euvolaemic hyponatraemia.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19644472     DOI： 10.1038/nrd2946

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  10 in total

Review 1.  Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists.

Authors:  Sheldon Chen; Nishant Jalandhara; Daniel Batlle
Journal:  Nat Clin Pract Nephrol       Date:  2007-02

2.  OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.

Authors:  Y Yamamura; S Nakamura; S Itoh; T Hirano; T Onogawa; T Yamashita; Y Yamada; K Tsujimae; M Aoyama; K Kotosai; H Ogawa; H Yamashita; K Kondo; M Tominaga; G Tsujimoto; T Mori
Journal:  J Pharmacol Exp Ther       Date:  1998-12       Impact factor: 4.030

3.  Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia.

Authors:  Toshiki Miyazaki; Yoshitaka Yamamura; Toshiyuki Onogawa; Shigeki Nakamura; Shizuo Kinoshita; Sunao Nakayama; Hiroyuki Fujiki; Toyoki Mori
Journal:  Endocrinology       Date:  2005-04-14       Impact factor: 4.736

4.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Authors:  Marvin A Konstam; Mihai Gheorghiade; John C Burnett; Liliana Grinfeld; Aldo P Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Thomas Cook; John Ouyang; Christopher Zimmer; Cesare Orlandi
Journal:  JAMA       Date:  2007-03-25       Impact factor: 56.272

5.  Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Authors:  Robert W Schrier; Peter Gross; Mihai Gheorghiade; Tomas Berl; Joseph G Verbalis; Frank S Czerwiec; Cesare Orlandi
Journal:  N Engl J Med       Date:  2006-11-14       Impact factor: 91.245

6.  7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.

Authors:  K Kondo; H Ogawa; H Yamashita; H Miyamoto; M Tanaka; K Nakaya; K Kitano; Y Yamamura; S Nakamura; T Onogawa; T Mori; M Tominaga
Journal:  Bioorg Med Chem       Date:  1999-08       Impact factor: 3.641

Review 7.  Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].

Authors:  Farhan Ali; M Adnan Raufi; Barbara Washington; Jalal K Ghali
Journal:  Cardiovasc Drug Rev       Date:  2007

Review 8.  Mechanisms, risks, and new treatment options for hyponatremia.

Authors:  Jalal K Ghali
Journal:  Cardiology       Date:  2008-04-25       Impact factor: 1.869

Review 9.  Therapeutic potential of vasopressin receptor antagonists.

Authors:  Farhan Ali; Maya Guglin; Peter Vaitkevicius; Jalal K Ghali
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.

Authors:  James E Udelson; Frank A McGrew; Enrique Flores; Hassan Ibrahim; Stewart Katz; Gregory Koshkarian; Terrence O'Brien; Marvin W Kronenberg; Christopher Zimmer; Cesare Orlandi; Marvin A Konstam
Journal:  J Am Coll Cardiol       Date:  2007-05-18       Impact factor: 24.094
  10 in total
  6 in total

Review 1.  The roles of V1a vasopressin receptors in blood pressure homeostasis: a review of studies on V1a receptor knockout mice.

Authors:  Yoko Fujiwara; Akito Tanoue; Gozoh Tsujimoto; Taka-Aki Koshimizu
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

2.  Tolvaptan.

Authors:  Eline A Dubois; Robert Rissmann; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

Review 3.  The disconnect between phase II and phase III trials of drugs for heart failure.

Authors:  Muthiah Vaduganathan; Stephen J Greene; Andrew P Ambrosy; Mihai Gheorghiade; Javed Butler
Journal:  Nat Rev Cardiol       Date:  2013-01-08       Impact factor: 32.419

4.  Identification and characterization of an activating F229V substitution in the V2 vasopressin receptor in an infant with NSIAD.

Authors:  Eric Carpentier; Larry A Greenbaum; Driss Rochdi; Ravinder Abrol; William A Goddard; Daniel G Bichet; Michel Bouvier
Journal:  J Am Soc Nephrol       Date:  2012-09-06       Impact factor: 10.121

5.  Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients.

Authors:  Savina Nodari; Geoffrey T Jao; Jun R Chiong
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-05-10

6.  Tolvaptan in reversing worsening acute heart failure: A systematic review and meta-analysis.

Authors:  Lili Wang; Qianhui Zhang; Meixia Liu; Shuxia Chen; Shuang Han; Jing Li; Rongpin Du
Journal:  J Int Med Res       Date:  2019-11-04       Impact factor: 1.671
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.